Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Olumiant (baricitinib) tablets Right
  4. Are there any data about the use of Olumiant® (baricitinib) in pediatric patients with alopecia areata?
Search Olumiant (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Baricitinib

Olumiant® (baricitinib) tablets

1mg, 2mg, 4mg
Full Prescribing Information

baricitinib

1mg, 2mg, 4mg

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Are there any data about the use of Olumiant® (baricitinib) in pediatric patients with alopecia areata?

BRAVE-AA-PEDS is an ongoing clinical trial evaluating baricitinib in pediatric patients with severe alopecia areata. No results from this trial are available at this time.

US_cFAQ_BAR064C_PEDIATRIC_USAGE_AA
US_cFAQ_BAR064C_PEDIATRIC_USAGE_AA
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Baricitinib Prescribing Information

Baricitinib is not approved for use in pediatric patients with alopecia areata. Please see prescribing information for approved indication(s).

Ongoing Alopecia Areata Pediatric Trial

BRAVE-AA-PEDS (NCT05723198) is a Phase 3, double-blind placebo-controlled, randomized, study evaluating the efficacy, safety, and pharmacokinetics of baricitinib in children from 6 years to less than 18 years of age with severe or very severe alopecia areata (AA).1

The study is divided into 4 periods: 

  • a 5-week screening period 
  • a 36-week double-blind treatment period
  • an approximately 2-year long-term extension period, and
  • a 4-week post-treatment follow-up period.1

Approximately 595 patients will be randomized to 

  • baricitinib high dose
  • baricitinib low dose, or
  • placebo.1

Enrollment will be sequential by age group, with adolescents (12 to <18 years old) enrolling prior to children (6 to <12 years old).2

Inclusion and Exclusion Criteria

Inclusion Criteria

Patients 6 years to <18 years of age enrolled in the study must have

  • severe AA for at least 1 year
  • Severity of Alopecia Tool (SALT) score of ≥50% at screening and baseline (hair loss encompassing at least 50% of the scalp)
  • current AA episode of at least 6 months durations with hair loss of ≥50% of the scalp
  • current episode of severe AA <8 years (patients who have severe AA for ≥8 yeas may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed over the past 8 years)
  • history of trial and failure with ≥1 available treatment (topical or other) for AA
  • history of psychological counseling related to AA.1

Key Exclusion Criteria

Patients are excluded if they 

  • have primarily "diffuse" type of AA (characterized by diffuse hair shedding)
  • are currently experiencing other forms of alopecia including, but not limited to:
    • trichotillomania,
    • telogen effluvium,
    • chemotherapy-induced hair loss, or
    • any other concomitant conditions that would interfere with the evaluations of the effect of study medication on AA.1

Primary Outcomes

The primary efficacy out is the proportion of patients achieving SALT ≤20 (≤20% scalp hair loss or ≥80% of scalp coverage with hair) at week 36.1

Key Secondary Outcomes

In addition to safety and pharmacokinetics, major secondary efficacy outcomes include changes, compared to placebo, in

  • other SALT endpoints
  • Clinician-Reported Outcome (ClinRO) Measures for eyebrow and eyelash hair loss, and
  • Patient-Reported Outcome (PRO) for scalp hair assessment, eyebrow and eyelash hair loss.1

BRAVE-AA-PEDS will also assess changes in anxiety and depression, and social and family related quality of life. 1

Available Data From the Baricitinib Alopecia Areata Phase 3 Clinical Trials

The efficacy and safety of baricitinib have been evaluated in the following pivotal, phase 3, placebo-controlled trials in adult patients with severe alopecia areata (AA)

  • BRAVE-AA1 (N=654) compared baricitinib 2 mg or 4 mg to placebo in adult patients with ≥50% scalp hair loss, and
  • BRAVE-AA2 (N=546) compared baricitinib 2 mg or 4 mg to placebo in adult patients with ≥50% scalp hair loss.3

To be included in BRAVE-AA1 or BRAVE-AA2, patients were required to be at least 18 years old. Pediatric patients were not eligible for enrollment.3

Therefore, no efficacy or safety data are available for pediatric patients from the BRAVE-AA1 and BRAVE-AA2 trials.

Enclosed Prescribing Information

OLUMIANT® (baricitinib) tablets, for oral use, Lilly

Reference

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1A study of baricitinib (LY3001904) in children from 6 years to less than 18 years of age with alopecia areata (BRAVE-AA-PEDS). ClinicalTrials.gov identifier: NCT05723198. Updated February 10, 2023. Accessed February 10, 2023. https://clinicaltrials.gov/ct2/show/NCT05723198.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3King B, Ohyama M, Kwon O, et al; BRAVE-AA investigators. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687-1699. https://doi.org/10.1056/nejmoa2110343

Date of Last Review: February 10, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly